Citation Impact
Citing Papers
Effect of Clopidogrel Added to Aspirin in Patients with Atrial Fibrillation
2009 Standout
Guidelines for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack
2014 Standout
2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease
2014 Standout
Identification and Characterization of Pharmacological Chaperones to Correct Enzyme Deficiencies in Lysosomal Storage Disorders
2011
Compliance assessment in drug trials: has there been improvement in two decades?
2005
Evidence of the Existence of a New Circulating Recombinant Form of HIV Type 1 Subtype A/J in Cameroon
2000 StandoutNobel
2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease
2014 Standout
2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: Executive Summary
2014 Standout
Comparison of prothrombin time (INR) results and main characteristics of patients on warfarin treatment in primary health care centers and anticoagulation clinics
2013 StandoutNobel
Improved Efficacy in a Fabry Disease Model Using a Systemic mRNA Liver Depot System as Compared to Enzyme Replacement Therapy
2019
Antithrombotic Therapy for Venous Thromboembolic Disease
2008 Standout
The Pharmacological Chaperone AT2220 Increases Recombinant Human Acid α-Glucosidase Uptake and Glycogen Reduction in a Mouse Model of Pompe Disease
2012
Small-Vessel Vasculitis
1997 Standout
Enhancing adherence in clinical research
2005
Lipid nanoparticles for mRNA delivery
2021 Standout
The role of autophagy in neurodegenerative disease
2013 Standout
Effects of the oral, direct thrombin inhibitor dabigatran on five common coagulation assays
2010 StandoutNobel
Refining Clinical Risk Stratification for Predicting Stroke and Thromboembolism in Atrial Fibrillation Using a Novel Risk Factor-Based Approach
2009 Standout
Prevention of VTE in Orthopedic Surgery Patients
2012 Standout
The effects of canagliflozin on gout in type 2 diabetes: a post-hoc analysis of the CANVAS Program
2019
New Antithrombotic Drugs
2008
Oral Anticoagulant Therapy
2012 Standout
SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials
2013 Standout
Therapeutic applications of compounds in the Magnolia family
2011 Standout
Antithrombotic Therapy for VTE Disease
2016 Standout
The natural history of azathioprine compliance after renal transplantation
2001
Prevention of VTE in Nonsurgical Patients
2012 Standout
Poor Adherence with Hypolipidemic Drugs: A Lost Opportunity
2001
Innovation in the pharmaceutical industry: New estimates of R&D costs
2016 Standout
Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism
2009 Standout
Antithrombotic Therapy for VTE Disease
2012 Standout
GRADE guidelines: 3. Rating the quality of evidence
2011 Standout
Efficacy of Adding Indinavir to Previous Reverse Transcriptase Nucleoside Analogues in Relation to Genotypic and Phenotypic Resistance Development in Advanced HIV-1-Infected Patients
1998
Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients
2009 Standout
Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial
2007
Dabigatran versus Warfarin in Patients with Atrial Fibrillation
2009 Standout
Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa
2006 Standout
Effect of point-of-care computer reminders on physician behaviour: a systematic review
2010 Standout
Rivaroxaban versus Enoxaparin for Thromboprophylaxis after Hip Arthroplasty
2008 Standout
Impact of Medication Adherence on Hospitalization Risk and Healthcare Cost
2005 Standout
Reporting of Noninferiority and Equivalence Randomized Trials
2012 Standout
A meta-analysis of the association between adherence to drug therapy and mortality
2006 Standout
Knowledge translation of research findings
2012 Standout
Signaling does not adequately improve diary compliance
2003
Tuberculosis and HIV infection in sub-Saharan Africa
1992
Antithrombotic Therapy in Atrial Fibrillation
2008
2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline From the American Heart Association/American Stroke Association
2021 Standout
Nanomaterial Delivery Systems for mRNA Vaccines
2021 StandoutNobel
Audit and feedback: effects on professional practice and healthcare outcomes
2012 Standout
Assessment Methods for Patient-Reported Outcomes
2003
Pharmacological chaperone therapy for Fabry disease
2012
WEGENER'S GRANULOMATOSIS
1995
1993 Revised Classification System for HIV Infection and Expanded Surveillance Case Definition for AIDS Among Adolescents and Adults
1993 Standout
Dissemination and publication of research findings: an updated review of related biases
2010 Standout
Interventions for enhancing medication adherence
2008 Standout
Guidelines for the Primary Prevention of Stroke
2014 Standout
Printed educational materials: effects on professional practice and healthcare outcomes
2012 Standout
Preventing Recurrence of Thromboembolic Events through Coordinated Treatment in the District of Columbia
2011
Ecological Momentary Assessment
2007 Standout
Interventions for enhancing medication adherence
2014 Standout
Gout
2021 Standout
Natural product and natural product derived drugs in clinical trials
2014 Standout
Effectiveness and efficiency of guideline dissemination and implementation strategies
2004 Standout
2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation
2015 Standout
Evolution and Clinical Pathologic Correlations of De Novo Donor-Specific HLA Antibody Post Kidney Transplant
2012 Standout
Strategies to Measure and Improve Patient Adherence in Clinical Trials
2009
Guidelines for the Prevention of Stroke in Patients With Stroke or Transient Ischemic Attack
2010 Standout
Medication Adherence
2009 Standout
Major joint replacement. A model for antithrombotic drug development: from proof-of-concept to clinical use.
2008
Works of Pol Boudes being referenced
A Randomized, Double‐Blind, Active‐ and Placebo‐Controlled Efficacy and Safety Study of Arhalofenate for Reducing Flare in Patients With Gout
2016
An analysis of the impact of FDA's guidelines for addressing cardiovascular risk of drugs for type 2 diabetes on clinical development
2011
The challenges of new drugs benefits and risks analysis: Lessons from the ximelagatran FDA Cardiovascular Advisory Committee
2006
Drug Compliance in Therapeutic Trials
1998
Migalastat HCl Reduces Globotriaosylsphingosine (Lyso-Gb3) in Fabry Transgenic Mice and in the Plasma of Fabry Patients
2013
Mediastinal tumour as the presenting manifestation of Wegener's granulomatosis
1990
The Pharmacodynamics, Pharmacokinetics, and Safety of Arhalofenate in Combination with Febuxostat When Treating Hyperuricemia Associated with Gout
2016
A randomized controlled trial of a protease inhibitor (saquinavir) in combination with zidovudine in previously untreated patients with advanced HIV infection.
1996
A pharmacogenetic approach to identify mutant forms of α‐galactosidase a that respond to a pharmacological chaperone for Fabry disease
2011
Disseminated Mycobacterium bovis Infection From BCG Vaccination and HIV Infection
1989
Pharmacokinetics and muscle distribution of AT2220, a pharmacological chaperone of acid-glucosidase, in healthy volunteers
2011